Mr. Patel commented, “The poster presented at the SABCS is important because the Kaplan Meier survival curves and demographic data further validate our promising HER2 3+ Phase IIb data and ...

"The stories behind the data are what makes this poster interesting," explains Timm Kekeritz, the designer who led the effort. "We wish we had time to collect more." Kekeritz says that the poster ...

The Poster submission was accepted by SABCS on September 15, 2021 and summarized the previously-disclosed Phase I/IIa clinical and pathological data from the clinical studies of the Bria-IMT ...

In addition, we are excited to enroll the safety component of the NC410 combo trial and to report initial data in mid-2023.” Details of the poster presentations are below: A phase 1/2 ...

In addition, Immutep plans to hold a webcast after ASCO to discuss the data and results, as well as to provide an update on the Company’s business. TACTI-002 Posters Title: Results from a ...

“We are excited to continue to share new preclinical data with the Hepatitis B medical community at this important conference as we progress our therapeutic vaccine candidate, CLB-3000, toward ...

The data suggest that CID-078 holds promise as a monotherapy for patients with these cancers, which will be evaluated in a phase 1 clinical trial. The digital poster can be viewed here.

Poster will describe loss of detectable HPV-6 in Recurrent Respiratory Papillomatosis patients following treatment with INO-3107 PLYMOUTH MEETING, Pa., Feb. 10, 2025 /PRNewswire/ -- INOVIO (NASDAQ ...

Data on the neoadjuvant ONO-4578 (EP4 antagonist) in combination with nivolumab for rectal cancer will be presented in a poster session. Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka ...

Mr. Patel commented, “The poster presented at the SABCS is important because the Kaplan Meier survival curves and demographic data further validate our promising HER2 3+ Phase IIb data and ...